Atypical HUS caused by anti-complement factor H antibody: a hematologist's perspective

نویسندگان

  • Meet Kumar
  • Prakas Mandal
  • Rajib De
  • Pinaki Mukherjee
  • Tuphan Kanti Dolai
  • Maitryee Bhattyacharyya
چکیده

Hemoglobin 4.5 g/dL 11.5–15.5 g/dL MCV 98 fL 77–94 fL RBC count 3.2×10/L 4.0–5.2×1012/L Total leukocyte count 10.3×10/L 5.0–13.0×109/L Platelet count 60×10/L 170–450×109/L Reticulocyte production index 7.2 0.5–2.5 Urea 284 mg/dL 20–40 mg/dL Creatinine 6.1 mg/dL 1–2 mg/dL Uric acid 24.1 mg/dL 2–4 mg/dL Total bilirubin 3.3 mg/dL Up to 1.0 mg/dL AST 127 U/L 0–35 U/L ALT 30 U/L 0–35 U/L LDH 3,876 U/L 100–190 U/L Direct Coombs test Negative Negative PNH clone (FLAER) Negative ANA, dsDNA Negative C3 complement levels 35 mg/dL 75–135 mg/dL Stool culture No growth -

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

Several studies have demonstrated genetic predisposition in non-shigatoxin-associated hemolytic uremic syndrome (HUS), involving regulatory proteins of the complement alternative pathway: Factor H (FH) and membrane co-factor protein (CD46). Regarding the observations of thrombotic thrombocytopenic purpura patients, in whom a von Willebrand factor protease (ADAMST-13) deficiency may be inherited...

متن کامل

Atypical hemolytic uremic syndrome due to factor H autoantibody.

Atypical hemolytic uremic syndrome (aHUS) is a disease caused by pathologies in the alternative complement system. The prevalence of aHUS is 10% of all aHUS cases. The subgroup of aHUS designated as DEAP (DEficiency of CFHR Proteins and CFH Autoantibody Positive)-HUS because of autoantibody to complement factor H (CFH) and CFH-related protein deficiency is seen very rarely, and the prevalence i...

متن کامل

Atypical hemolytic uremic syndrome

Hemolytic uremic syndrome (HUS) is defined by the triad of mechanical hemolytic anemia, thrombocytopenia and renal impairment. Atypical HUS (aHUS) defines non Shiga-toxin-HUS and even if some authors include secondary aHUS due to Streptococcus pneumoniae or other causes, aHUS designates a primary disease due to a disorder in complement alternative pathway regulation. Atypical HUS represents 5 -...

متن کامل

Thrombotic microangiopathy after kidney transplantation.

Thrombotic microangiopathy (TMA) is a severe complication of kidney transplantation that often causes graft failure. TMA may occur de novo, often triggered by immunosuppressive drugs and acute antibody-mediated rejection, or recur in patients with previous history of hemolytic uremic syndrome (HUS). Recurrent TMA is very rare in patients who had developed end-stage renal failure following HUS c...

متن کامل

Clinical Relapses of Atypical HUS on Eculizumab: Clinical Gap for Monitoring and Individualised Therapy

Atypical hemolytic uremic syndrome (aHUS) is caused by dysregulation of the complement system. A humanised anti-C5 monoclonal antibody (eculizumab) is available for the treatment of aHUS. We present the first description of atypical HUS in a child with a coexistent diagnosis of a POL-III leukodystrophy. On standard eculizumab dosing regime, there was evidence of ongoing C5 cleavage and clinical...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 50  شماره 

صفحات  -

تاریخ انتشار 2015